Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
GBP1 CRISPR/Cas9 KO Plasmid (h): sc-401778
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GBP1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GBP1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GBP1 Antibody (1B1): sc-53857
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GBP1 CRISPR/Cas9 KO Plasmid (h) | sc-401778 | 20 µg | $397.00 |
Overview
Guanylate binding protein 1 (GBP1) is a large interferon-inducible dynamin-like GTPase that acts as an effector of innate immunity. It is robustly upregulated downstream of JAK/STAT signaling in response to type I and type II interferons and participates in cell-autonomous defense by targeting pathogen-containing compartments and modulating antimicrobial and inflammatory programs. GBP1 has been linked to processes including inflammasome-related responses, intracellular trafficking, and cytoskeletal remodeling, with context-dependent roles in epithelial barrier biology and immune cell activation. Altered GBP1 expression is frequently observed in chronic inflammatory states, infectious disease models, and tumor-associated immune microenvironments, making it a useful node for studying interferon-stimulated gene (ISG) networks.
GBP1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GBP1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GBP1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GBP1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GBP1 protein expression.
This CRISPR knockout system enables efficient generation of GBP1-deficient cell models for investigation of GBP1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting GBP1 exon(s) critical for GBP1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple GBP1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GBP1 CRISPR/Cas9 KO Plasmid (h) and GBP1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GBP1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GBP1 HDR Plasmid (h) and GBP1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GBP1 homology arms to support homology-directed repair at defined GBP1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.